Price
Financials
Standalone, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 39.54 | 43.11 | 38.64 | 32.21 | 26.09 | 29.55 | 25.50 | 23.81 | 26.65 | 22.18 | 33.16 | 27.96 |
| Expenses | 36.47 | 39.59 | 34.17 | 28.98 | 23.19 | 26.97 | 22.39 | 20.91 | 24.65 | 19.71 | 30.22 | 25.44 |
| Operating Profit | 3.07 | 3.52 | 4.47 | 3.23 | 2.90 | 2.58 | 3.11 | 2.90 | 2.00 | 2.47 | 2.94 | 2.52 |
| OPM % | 7.76% | 8.17% | 11.57% | 10.03% | 11.12% | 8.73% | 12.20% | 12.18% | 7.50% | 11.14% | 8.87% | 9.01% |
| Other Income | 0.00 | -0.01 | 0.08 | 0.77 | 0.01 | 0.10 | 0.11 | 0.01 | 0.64 | 0.27 | 0.25 | 0.15 |
| Interest | 1.30 | 1.27 | 1.23 | 1.44 | 1.08 | 1.11 | 1.11 | 1.00 | 0.91 | 1.11 | 0.96 | 0.90 |
| Depreciation | 0.49 | 0.50 | 0.53 | 0.55 | 0.58 | 0.64 | 0.67 | 0.60 | 0.60 | 0.61 | 0.61 | 0.59 |
| Profit before tax | 1.28 | 1.74 | 2.79 | 2.01 | 1.25 | 0.93 | 1.44 | 1.31 | 1.13 | 1.02 | 1.62 | 1.18 |
| Tax % | 32.81% | 29.89% | 4.66% | 18.91% | 12.80% | 16.13% | 38.19% | 19.85% | 10.62% | 25.49% | 20.37% | 5.93% |
| Net Profit | 0.86 | 1.22 | 2.66 | 1.63 | 1.09 | 0.77 | 0.89 | 1.04 | 1.00 | 0.76 | 1.29 | 1.11 |
| EPS in Rs | 1.14 | 1.62 | 3.53 | 2.16 | 1.45 | 1.02 | 1.18 | 1.38 | 1.33 | 1.01 | 1.27 | 1.10 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 71 | 76 | 64 | 84 | 96 | 123 | 161 | 160 | 157 | 113 | 106 | 110 |
| Expenses | 67 | 70 | 60 | 78 | 90 | 113 | 150 | 150 | 143 | 102 | 95 | 100 |
| Operating Profit | 4 | 5 | 4 | 5 | 6 | 10 | 11 | 10 | 13 | 12 | 10 | 10 |
| OPM % | 6% | 7% | 6% | 7% | 6% | 8% | 7% | 6% | 8% | 10% | 10% | 9% |
| Other Income | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
| Interest | 2 | 3 | 2 | 3 | 3 | 3 | 3 | 4 | 5 | 5 | 4 | 4 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | 2 | 3 | 1 | 2 | 2 | 6 | 7 | 5 | 7 | 6 | 5 | 5 |
| Tax % | 38% | 33% | 37% | 31% | 13% | 28% | 25% | 23% | 20% | 22% | 19% | |
| Net Profit | 1 | 2 | 1 | 1 | 2 | 4 | 5 | 4 | 6 | 4 | 4 | 4 |
| EPS in Rs | 1.79 | 2.40 | 1.10 | 1.61 | 2.66 | 5.48 | 6.97 | 5.03 | 7.37 | 5.82 | 4.04 | 4.71 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | 4% | -3% | -13% | 5% | ||
| Compounded Profit Growth | 10% | -2% | 0% | 3% | ||
| Stock Price CAGR | 11% | 12% | 10% | 39% | ||
| Return on Equity | 11% | 12% | 10% | 6% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 10 |
| Reserves | 6 | 7 | 9 | 10 | 11 | 13 | 17 | 22 | 26 | 31 | 36 | 66 |
| Borrowings | 8 | 16 | 16 | 19 | 22 | 28 | 30 | 23 | 36 | 58 | 64 | 82 |
| Other Liabilities | 13 | 21 | 24 | 27 | 33 | 36 | 36 | 49 | 52 | 38 | 35 | 43 |
| Total Liabilities | 35 | 51 | 56 | 63 | 74 | 84 | 91 | 101 | 121 | 135 | 143 | 200 |
| Fixed Assets | 7 | 9 | 13 | 15 | 15 | 14 | 22 | 26 | 25 | 27 | 33 | 30 |
| CWIP | 0 | 1 | 0 | 1 | 2 | 9 | 1 | 0 | 9 | 18 | 30 | 57 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 27 | 41 | 43 | 47 | 57 | 61 | 68 | 75 | 87 | 90 | 81 | 114 |
| Total Assets | 35 | 51 | 56 | 63 | 74 | 84 | 91 | 101 | 121 | 135 | 143 | 200 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | -6 | -5 | 5 | 4 | 4 | 6 | 1 | 11 | 13 | 18 | 11 | 1 |
| Cash from Investing Activity | -0 | -2 | -3 | -3 | -2 | -7 | -1 | -5 | -9 | -13 | -20 | -26 |
| Cash from Financing Activity | 6 | 7 | -2 | -0 | -1 | 0 | 0 | -6 | -4 | -6 | 8 | 37 |
| Net Cash Flow | 0 | 0 | 0 | 1 | -0 | -0 | 0 | 1 | 1 | -0 | -0 | 12 |
| Free Cash Flow | -6 | -7 | 1 | 0 | 1 | -1 | -0 | 6 | 4 | 5 | -9 | -26 |
| CFO/OP | -101% | -101% | 108% | 109% | 73% | 108% | 26% | 110% | 143% | 146% | 105% | 19% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 87 | 126 | 117 | 152 | 148 | 137 | 134 | 126 | 132 | 138 | 136 | 150 |
| Inventory Days | 84 | 67 | 70 | 100 | 93 | 84 | 55 | 28 | 57 | 62 | 125 | 217 |
| Days Payable | 79 | 108 | 124 | 171 | 171 | 144 | 112 | 121 | 132 | 96 | 128 | 163 |
| Cash Conversion Cycle | 92 | 85 | 63 | 81 | 70 | 78 | 78 | 33 | 58 | 105 | 133 | 204 |
| Working Capital Days | 63 | 44 | 40 | 47 | 38 | 31 | 46 | 32 | 23 | 9 | 11 | 42 |
| ROCE % | 32% | 16% | 17% | 11% | 12% | 12% | 18% | 18% | 14% | 14% | 10% | 7% |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 53.16% | 53.16% | 53.16% | 53.16% | 52.63% | 52.63% | 52.63% | 52.63% | 52.61% | 52.61% | 40.23% | 40.23% |
| DIIs | 0.50% | 0.50% | 0.50% | 0.50% | 0.50% | 0.50% | 0.50% | 0.50% | 0.50% | 0.50% | 2.47% | 2.74% |
| Public | 46.33% | 46.35% | 46.34% | 46.34% | 46.87% | 46.87% | 46.87% | 46.87% | 46.90% | 46.89% | 57.31% | 57.04% |
| No. of Shareholders | 7,019 | 6,894 | 7,005 | 7,044 | 7,709 | 7,915 | 7,881 | 7,828 | 7,720 | 7,483 | 7,300 | 6,722 |
Fundamentals
Market Cap₹ 132 Cr.
Current Price₹ 120
Stock P/E33.8
Book Value₹ 74.8
ROCE6.55 %
ROE6.14 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)5%
Compounded Profit Growth (TTM)3%
Standalone figures.
Valuation
Market capRs 120 Cr
Enterprise valueRs 187 Cr
P/E (TTM)28.74x
Price to book1.58x
Price to sales1.09x
EV / EBITDA16.64x
EV / EBIT21.18x
EV / sales1.70x
Price to cash flow163.77x
Earnings yield3.48%
P/E, 3-year average16.32x
P/B, 3-year average1.49x
P/E, 5-year average14.68x
P/B, 5-year average1.57x
Profitability
Operating margin (excl. other income)9.75%
Operating margin (incl. other income)10.85%
EBITDA margin10.22%
Pre-tax margin4.50%
Net profit margin3.78%
Net margin, latest quarter3.97%
ROE6.87%
ROCE6.82%
ROA2.38%
ROE, 3-year average10.95%
ROCE, 3-year average10.41%
ROA, 3-year average3.29%
ROE, 5-year average12.86%
ROCE, 5-year average12.82%
ROA, 5-year average3.74%
ROIC (approx.)4.99%
Tax rate19.13%
Other income / net worth1.53%
Growth
Sales growth (latest year)-6.65%
Profit growth (latest year)-6.62%
Sales CAGR, 3 years-12.81%
Sales CAGR, 5 years-2.91%
Profit CAGR, 3 years2.57%
Profit CAGR, 5 years-0.19%
Sales growth QoQ-15.68%
Profit growth QoQ-13.95%
Sales growth YoY (latest quarter)17.43%
Profit growth YoY (latest quarter)6.73%
Per share
EPS (TTM)Rs 4.11
EPS (latest year)Rs 4.04
EPS (latest quarter)Rs 1.10
EPS, 3-year averageRs 5.74
EPS, 5-year averageRs 5.85
Book value per shareRs 74.85
Sales per shareRs 108.57
Cash flow per shareRs 0.72
Free cash flow per shareRs -25.67
Efficiency
Asset turnover0.53x
Fixed asset turnover3.49x
Inventory turnover1.84x
Inventory days198 days
Debtor days150 days
Debtors turnover2.43x
Creditor days163 days
Cash conversion cycle204 days
Working capital days42 days
Leverage
Total debtRs 82 Cr
Cash and bankRs 15 Cr
Net debtRs 67 Cr
Debt to equity1.08x
Net debt / EBITDA6.00x
Interest coverage2.28x
Owners' fund to total sources37.82%
Debt to assets40.88%
Cash flow
Cash from Operating Activity (latest year)Rs 1 Cr
Cash from Investing Activity (latest year)Rs -26 Cr
Cash from Financing Activity (latest year)Rs 37 Cr
Net Cash Flow (latest year)Rs 12 Cr
Free cash flow (latest year)Rs -26 Cr
FCFE (approx.: FCF + change in debt)Rs -8 Cr
Cash from ops / profit, 5 years2.35x
Sales to cash flow144.95x
Statement figures
Net sales (TTM)Rs 110 Cr
Net sales (latest year)Rs 106 Cr
Sales (latest quarter)Rs 28 Cr
Operating profit excl. other income (latest year)Rs 10 Cr
Operating profit (latest quarter)Rs 3 Cr
Other income (TTM)Rs 1 Cr
EBITDA (TTM)Rs 11 Cr
PBDT (TTM)Rs 7 Cr
Profit before tax (TTM)Rs 5 Cr
Tax (latest year)Rs 1 Cr
Net profit (TTM)Rs 4 Cr
Net profit (latest year)Rs 4 Cr
Net profit (latest quarter)Rs 1 Cr
Depreciation (TTM)Rs 2 Cr
Depreciation (latest quarter)Rs 1 Cr
Interest (TTM)Rs 4 Cr
Cost of goods sold (latest year)Rs 85 Cr
Total expenditure (latest year)Rs 95 Cr
Total income (latest year)Rs 107 Cr
Share capitalRs 10 Cr
ReservesRs 66 Cr
Shareholders' fundsRs 76 Cr
Total assetsRs 200 Cr
Net blockRs 30 Cr
Capital work in progressRs 57 Cr
ReceivablesRs 44 Cr
InventoryRs 46 Cr
Other liabilitiesRs 43 Cr
Shares outstanding (crore)1.01
Ownership
Promoter holding40.23% (-12.40 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 28.7 is at the 89th percentile of its own 9.4-year range
(median 20.7, low 9.6, high 33.9).
P/B 1.58 is at the 24th percentile (median 2.24).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | 530317 | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | +7.4% | -2.8% | +10.2 pts |
| 1 month | +20.5% | -6.8% | +27.3 pts |
| 3 months | -2.1% | -7.6% | +5.5 pts |
| 3 years | +29.0% | +14.2% | +14.8 pts |
| 5 years | +71.5% | +27.9% | +43.6 pts |
Red flags
F-score 3 of 8| explain | Share dilution Share count up 35% in a year, 35% in three |
| look | Inventory outrunning sales Inventory grew 65% vs sales -7% in 2026 |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹28 Cr +17.4% vs Jun 2025.
Net profit ₹1 Cr +6.7%.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Godavari Drugs Ltd?
Godavari Drugs Ltd (530317) has a market capitalisation of Rs 132 Cr. at the 2026-10-01 close.
What is the P/E ratio of Godavari Drugs Ltd?
Godavari Drugs Ltd trades at a P/E of 33.8 on trailing twelve-month profit, at the 2026-10-01 close.
What were Godavari Drugs Ltd's latest quarterly results?
In the Jun 2026 quarter, Godavari Drugs Ltd sales was Rs 28 Cr (+17.4% vs Jun 2025) and net profit was Rs 1 Cr.